The efficacy of herbal medicine Khar Maryam (Silybum marianum (L.) Gaertn.) on liver cirrhosis in chronic hepatitis B patients

Journal of Medicinal Plants

Volumn 4, Issue SUPPL. 1, 2005, Pages 1-6

  Fallah Huseini, H ^a,g   Alavian, S M ^b   Toliat, T ^c   Jamshidi, A H ^a   Heshmat, R ^d   Naghdi Badi, H ^e   Khani, M ^f  

^a Institute of Medicinal Plants Iran   (Iran)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF TEHRAN   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TARBIAT MODARES UNIVERSITY   (Iran)

^f AVICENNA RESEARCH INSTITUTE   (Iran)

^g NONE   (Iran)

Author keywords

Cirrhosis; Clinical trial; Herbal medicine silymarin; Khar maryam

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; PLACEBO; SILYBUM MARIANUM EXTRACT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEPATITIS B; HERBAL MEDICINE; HUMAN; LEUKOCYTE COUNT; LIVER CIRRHOSIS; LIVER PROTECTION; MAJOR CLINICAL STUDY; MORTALITY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SILYBUM MARIANUM; THROMBOCYTE COUNT; TREATMENT OUTCOME;

SILYBUM MARIANUM;

EID: 20444484833     PISSN: 2717204X     EISSN: 27172058     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hoofnagle JH and Di Bisceglie AM. Treatment of chronic viral hepatitis. N Engl J Med. 1997; 33 (12): 347-512.
2. Patrick LND. Hepatitis C: Epidemiology and review of complementary/ alternative medicine treatments. Alter. Med. Rev. 1999; 4 (4): 220-238.
3. Castelman M. A possible remady for liver disease. J. Mother. Jones. 1999; 10-14.
4. Mourelle M, Muriel p, Favori L, franco T. Prevention of CC14 -induced liver cirrhosis by silymarin. Fundam. Clin. Pharmacol. 1989; 3: 183-91.
5. Clot p, Tabone N, Arico S, Albano E. Monitoring oxidative damage in patients with liver cirrhosis and different daily alcohol intake. Gut. 1994; 35: 1637-43.
6. Halim A-B and El-Ahmady O. Biochemical effect of antioxidants on lipids and liver function in experimentally- induced liver damage. Ann. Clin. Biochem. 1997; 34: 656-663
7. Schuppan D, Lang T, Gerling G, Langpeschlow E. Krumbiegel G, Reicken Eo. Antifibrotic effect of silymarin in rat secondary biliary fibrosis induced by duct obliteration with ethibloc Z. Gastroenterol. 1994; 32: 45-6.
8. Flora K and Hahn M. Milk thistle (Silybum marianum) for the therapy of liver disease. Am. J. Gastroenterol. 1998; 93 (2): 139-43.
9. Luper S. Areview of plants used in the treatment of liver disease: part 1. Altern. Med Rev. 1998; 12: 410-21.
10. Ferenci p, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J. Hepatol. 1989; 9: 105-11.
11. Cabrera C. Milk Thistle: A clinician's report. Medical Herbalism. 1994; 6: 11-5.
12. Vogel G, Tuchweber B, Trost W, Mengs U. Protection by silibinin against Amanita phalloides intoxication in Beagles. Toxicol. Appl. pharmacol. 1984; 73: 355-62.
13. Vogle G. Studies on pharmacodynamics, site and mechanism of action of silymarin the antihepatotoxic principale from Silybum marianum (L.) Gaert. Arzneim. Forsch. 1975; 25: 179-185.
14. Schonfeld J.V, Weisbrod B, Muller MK. Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin toxicity. CMLS. 1997; 53: 917-920.
15. McIntyre N. Plasma lipids and lipoproteins in liver diseases. Gut. 1987; 19: 526-530.
16. Lang I, Nekam K, Deak G, Ger-gely P, Csomos G. Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers. Ital. J. Gastroenterol. 1990; 22: 283-287.
17. Campos R and Garrido A. Silybin dihemsuccinate protects against glutathioine depletion and lipid peroxidation induced by acetaminophen on rat liver. Plant Meidca. 1998; 55: 417-9.